Drug Discovery World
SEPTEMBER 8, 2023
News round-up for 4-8 September by DDW Digital Content Editor Diana Spencer. This week we have seen the vital importance of collaboration to the successful development and discovery of novel therapeutics, exemplified by the new deal agreed by the UK and EU to admit the UK back into Horizon Europe, the largest collaborative research programme in the world.
Chemical Biology and Drug Design
SEPTEMBER 8, 2023
Monocarboxylate transporters (MCTs) play a crucial role in cancer metabolism and progression, most notably MCT1 and MCT4. This review explores the heterocyclic and non-heterocyclic arena of MCT inhibitors in the battle against tumorigenesis. Heterocyclic compounds, such as indole, flavonoid, pyrazole, pteridine and coumarin, and non-heterocyclic compounds, including cyanoacetic acid derivatives and N-cyano sulphonamides, have shown promising potential as MCT inhibitors, offering new therapeutic
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 8, 2023
Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has been approved for use in individuals from six months of age.
BioPharma Drive: Drug Pricing
SEPTEMBER 8, 2023
Shape uses machine learning and high throughput screening to identify new AAV capsids in ways the company’s CEO compares to the generative AI tools Midjourney and DALLE-2.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
SEPTEMBER 8, 2023
The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). “As the first patient dosed with a Beam therapeutic candidate and the first patient in the US to receive a base editing therapeutic, this represents a major milest
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- Receiving an organ transplant can be a nerve-wracking, if lifesaving, affair, said Dr. Joaquin Brieva, a kidney transplant recipient. “Within two days of my transplant, my kidney function was back to normal, but then.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- It's well known that certain forms of birth control carry a small risk of blood clots. Now a large new study suggests that some common painkillers can magnify that risk. The study, of 2 million Danish women, found what.
BioPharma Drive: Drug Pricing
SEPTEMBER 8, 2023
The PASTEUR Act could be heading for another legislative blow, but advocates say they see a future for the mechanism to fund research into antimicrobial resistance.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- Therapies based on a hormone people make while exercising may be the next frontier in treating Alzheimer’s disease, according to a new study. Researchers have found that the exercise-induced hormone irisin may reduce both.
biobide
SEPTEMBER 8, 2023
Preclinical assays are a vital step in a drug’s journey to approval for use in human subjects. They allow drugs that are too toxic or unsafe to be filtered out in the Early Drug Discovery Phase prior to being tested on humans during the clinical phase. Also, Toxicology studies of the thousands of new chemical compounds there are being developed and the deeper study of others that are currently in use is of major relevance to ensure their safety.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- New Swedish research suggests that up to 5% of 70-year-olds have glaucoma, and half of those diagnosed didn't even know they had the disease. “Of those who were diagnosed with glaucoma via the study, 15 people -- or 2.7%.
Science Daily: Pharmacology News
SEPTEMBER 8, 2023
Researchers who created a soft robot that could navigate simple mazes without human or computer direction have now built on that work, creating a 'brainless' soft robot that can navigate more complex and dynamic environments.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- Philips Respironics has agreed to a partial $479 million settlement to users of CPAP machines that blew gases and flecks of foam into their mouths and lungs. Class action lawsuits against the company are ongoing, the New.
Drug Target Review
SEPTEMBER 8, 2023
New researched published in the journal Immunity , T cells exhibit an unusual, yet vital behaviour in their battle against pathogens and cancer cells, involving a nuclear receptor. This receptor, referred to as retinoic acid receptor alpha (RARα), is recognised for its regulation of gene expression within the nucleus. However, recent insights indicate that it also operates beyond the nucleus, orchestrating initial events at the cell surface that trigger the activation of T cells.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- Global warming has been linked to higher rates of asthma, heart disease and other health concerns. Now, new research suggests that rising temperatures across the planet may place pregnant women at greater risk for severe.
Drug Channels
SEPTEMBER 8, 2023
Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir discusses how hubs help patients initiate and adhere to drug therapies. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Learn more by downloading CareMetx’s full report: The Evolving Landscape of Digital Healthcare Hubs.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- The maker of the “One Chip Challenge” has pulled the product from store shelves after a Massachusetts mom claimed the super spicy chip, packaged in a coffin-shaped container, contributed to the death of her 14-year-old.
SCIENMAG: Medicine & Health
SEPTEMBER 8, 2023
September 8, 2023—(BRONX, NY)—Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine, effective October 2nd, 2023. Following a comprehensive national search, Dr. Tomer stood out as the clear choice to lead the College of Medicine amongst a group of highly accomplished and distinguished candidates.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- There's an adage that in romantic relationships, opposites attract. Now, a large, new study confirms that just like many old sayings, it's wrong.
SCIENMAG: Medicine & Health
SEPTEMBER 8, 2023
Developing new drugs is paramount in discovering innovative treatments and preventing diseases. This is vital not only for advancing medicine but also for the overall health and well-being of humanity. Yet, even when drugs demonstrate safety and efficacy in cell and animal models, they frequently encounter hurdles in clinical trials on human.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- Eczema and psoriasis are skin conditions that can each affect a person’s quality of life. The best way to know which one you have if you have an itchy rash or burning feeling on your skin is to see an expert. “Both.
Science Daily: Pharmacology News
SEPTEMBER 8, 2023
A new article hints at the existence of several black holes in the Hyades cluster -- the closest open cluster to our solar system -- which would make them the closest black holes to Earth ever detected.
Drugs.com
SEPTEMBER 8, 2023
FRIDAY, Sept. 8, 2023 -- Winter months can be a challenge for those trying to keep their high blood pressure in check, new research suggests. In an analysis of more than 60,000 American adults being treated for high blood pressure at six health care.
BioPharma Drive: Drug Pricing
SEPTEMBER 8, 2023
Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing “updates.
Cytel
SEPTEMBER 8, 2023
Single-arm trials, unlike placebo-controlled randomized control trials, forgo the use of a placebo or standard-of-care as a control and establish clinical benefit by demonstrating the effects of a new therapy or treatment via comparison with a synthetic control arm (SCA) derived from external sources. This alternative approach leverages real-world data from various sources or evaluations of historical trial data for the sake of comparison.
Perficient: Drug Development
SEPTEMBER 8, 2023
Aging Populations and Staff Burnout Combine to Create a Perfect Storm for Healthcare Staffing Shortage For the first time in US history, older adults will outnumber younger individuals. The global population is top-heavy with more than 1 in every 6 Americans falling in the 65 or older age range (AARP, 2023). As the population ages and we see a continued increase in patients with more than one chronic condition, the demand on healthcare providers is not going to lessen in the upcoming decades (CD
Common Sense for Drug Policy Blog
SEPTEMBER 8, 2023
Post-Decriminalization, Police Continue Seizing Drugs Even Without Making An Arrests "During the 16-month study period between June 2019 and November 2021 (June 2019–mid-March 2020 and June 2021–November 2021), 6% of our sample of people who used drugs daily in Vancouver reported having had their drugs seized by police without arrest at least once in the past 6 months.
SCIENMAG: Medicine & Health
SEPTEMBER 8, 2023
The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “A Precision-Health Approach to Bipolar Disorder” on Tuesday, September 12, 2023, at 2:00 pm EST. The presenter will be Sarah H. Sperry, Ph.D., Assistant Professor of Psychiatry and Adjunct Assistant Professor of Psychology at the University of Michigan. Dr.
Perficient: Drug Development
SEPTEMBER 8, 2023
Ever, while working on Sitecore SXA projects, we come across a requirement where we need to integrate a library in SXA without reinventing the wheel. Hence, we will check this thing using an example of integrating Bootstrap Modal in Sitecore SXA. So, multiple times, we encounter a need where some content must be displayed in pop-up. In this case instead of creating a custom Modal from scratch, we can use the Bootstrap Modal.
Common Sense for Drug Policy Blog
SEPTEMBER 8, 2023
Vancouver Police Persist In Seizing Drugs In Spite Of Decriminalization "Among 995 participants who were interviewed in 2019–2021, 63 (6.3%) had their drugs seized by police at least once in the past 6 months. In multivariable analyses, factors significantly associated with drug seizure included: homelessness (adjusted odds ratio [AOR]: 1.98; 95% confidence interval [CI] 1.09–3.61), working in the unregulated drug market (AOR: 4.93; 95% CI 2.87–8.49), and naloxone administration (AOR: 2.15; 95%
Alta Sciences
SEPTEMBER 8, 2023
Manufacturing of a Highly Potent API for an Ophthalmic Indication tchichekian Fri, 09/08/2023 - 11:50 Publication CDMO_Manufacturing of Highly Potent API.
Drug Patent Watch
SEPTEMBER 8, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Drug & Device Law
SEPTEMBER 8, 2023
As a defense lawyer, one grows accustomed to clear judicial days on which the state court can foresee forever. See Thing v. La Chusa , 48 Cal. 3d 644, 668 (1989). On those clear judicial days, when the court catches a glimpse of the possibility of harm shimmering off in the distance, one can be assured that an expansion of liability soon will follow.
Expert insights. Personalized for you.
130 
Let's personalize your content